Philip R. Dormitzer, M.D., Ph.D., is Head of US Research, Global Head of Virology, and Vice President at Novartis Vaccines and Diagnostics in Cambridge, Massachusetts. He is a practicing physician, board certified in Internal Medicine. After studying anthropology at Harvard College and carrying out a field study of the Efe Pygmies in the Ituri Forest of Zaire, Dr. Dormitzer completed his M.D. and Ph.D. degrees at Stanford University. His graduate research focused on rotavirus antigenic structure. Dr. Dormitzer completed house-staff training in Internal Medicine at Massachusetts General Hospital and a fellowship in the Harvard Combined Infectious Diseases Training Program. He conducted his fellowship research in the Laboratory of Molecular Medicine, led by Dr. Stephen Harrison. As an Assistant Professor of Pediatrics at Harvard Medical School, Dr. Dormitzer led a structural virology laboratory. The Dormitzer group and its collaborators determined the structures of the rotavirus neutralization antigens by NMR spectroscopy, X-ray crystallography, and near atomic resolution electron cryomicroscopy. At NV&D, as Senior Project Leader for Viral Vaccine Research, he had responsibility for global vaccine research projects on influenza, RSV, parvovirus B19, and other agents. In 2009, these projects included the research component of the Novartis response to the H1N1v influenza pandemic, supporting the development and licensure of three pandemic influenza vaccines in the most rapid vaccine response in history. As Head of the Viral Advanced Programs Global Team, he coordinated scientific and industrial functions to advance novel viral vaccine projects toward licensure, with a primary focus on an engineered RSV F subunit vaccine candidate, intended for maternal immunization. As Head of Research, US, he leads approximately 80 scientists, most based at the NV&D Cambridge Research Center, in their viral vaccine discovery mission.